key: cord-0841971-9v90jquj
authors: Grupper, Ayelet; Katchman, Helena
title: Reduced humoral response to mRNA SARS‐CoV‐2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely
date: 2021-06-18
journal: Am J Transplant
DOI: 10.1111/ajt.16710
sha: 129305d975fe93c6e050c4582526526dc5c5f515
doc_id: 841971
cord_uid: 9v90jquj

We greatly appreciate the time taken by S. Mossad1 to point out issues that are crucial in the field of transplant recipients' vaccination. The SARS-CoV-2 vaccines has been widely endorsed by solid-organ transplant societies and is recommended with a high priority to all transplant recipients and their immunocompetent household members2 . Nevertheless, there is concern, related to a potential reduction in the efficacy of the vaccine due to the chronic immunosuppression state.

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely To the Editor:

We greatly appreciate the time taken by S. Mossad 1 to point out issues that are crucial in the field of transplant recipients' vaccination.

The SARS-CoV-2 vaccines have been widely endorsed by solid organ transplant societies and are recommended with a high priority to all transplant recipients and their immunocompetent household members. 2 Nevertheless, there is a concern related to a potential reduction in the efficacy of the vaccine due to the chronic immunosuppression state.

We agree with S. Mossad that reduced response to vaccination in transplant recipients is not surprising, hence, his statement that our results are "no cause for alarm" is even more inconsistent. Our The aims of our study were not only to highlight the decreased humoral response in immunocompromised patients, but, and not less importantly, to define the most vulnerable individuals among kidney transplant recipients (i.e., older age, triple immunosuppression, high-dose steroid treatment, regimen that includes MMF).

Those patients should be the target for implementation of potential strategies to improve vaccine immune response. Our findings were not identical to the cohorts with reduced immune response to other vaccines, as cited by S. Mossad. 1 We believe that building confidence in the COVID-19 vaccine should be based on further data acquisition from all the immune response pathways, but until then, vaccinated transplant recipients should not assume immunity before precise testing of immune response and should be advocated to continue adherence to diligent mask use, hand hygiene, and social distancing. 

Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. No cause for alarm

American Society of Transplantation COVID-19 Vaccination Guidance

Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)

Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis

Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients